Sinovac - China Power gegen Schweinegrippe
Seite 2 von 5 Neuester Beitrag: 05.07.10 15:32 | ||||
Eröffnet am: | 30.05.09 16:22 | von: Leuwai | Anzahl Beiträge: | 101 |
Neuester Beitrag: | 05.07.10 15:32 | von: alice.im.börs. | Leser gesamt: | 22.816 |
Forum: | Börse | Leser heute: | 10 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 | 5 > |
man schaue sich nur mal die einzelaktionen an.
da müssen einige glauben , daß es nochmal richtig bergauf geht.
wer würde sonst bei nem kurs um die 9$ nochmal (nur zum beisiel) ne million raushauen ß
UNGLAUBLICH.
desderwegen bin ich gespannt was passiert wenn das mit der lizenz klappt !
uijuijuijuijui.
heute werden wahrscheinlich erst mal ein paar ihre schäfchen ins trockene bringen .
ABER dann !
kurs in deutschland bei 7,40.
schlußkurs gestern bei 9,71$ (entspricht 6,76 €)
also entweder kann ich nicht rechnen , oder da wissen einige schon wieder mehr. !
ist den gestern nochwas passiert ?
weiß jemand irgendwas ?
oder sind jetzt alle völlig durchgeknallt ?
http://www.stockwatch.com/utilit/utilit_snapsh_result.aspx
Kürzel :SVA Letzter: 11,23 USD
mc
Ärgerlich,dabei wollte ich noch rechtzeitig wieder hier rein, nur vorübergehend
woanders mitmischen und als es hier losging "parkte" ich immer noch woanders
und wollte natürlich nicht auf den rasenden Zug aufspringen, denn man weiß ja
nicht wann er stark abbremsen wird. :(
mc
Frank Phillipps
Erst gestern hatte DER AKTIONÄR das Kursziel für das Sinovac-Papier deutlich angehoben. Schon heute wurde die neue Zielmarke übertroffen. Was sollten Anleger jetzt mit dem Papier des chinesischen Impfstoffentwicklers tun?
Erst gestern hatte DER AKTIONÄR den Zielkurs für die Aktie von Sinovac deutlich von vier auf sechs Euro erhöht. Doch auch diese Zielmarke wurde sehr viel schneller übertroffen als erwartet. Im gestrigen US-Handel machte das Papier des chinesischen Impfstoff-Spezialisten einen erneuten Kurssprung um mehr als 50 Prozent.
Reaktion auf gute News
Die Börse honorierte damit zum einen die guten News der letzten Tage. Gesundheitsexperten aus China hatten sich dafür ausgesprochen, dass Sinovac die Lizenz zur Herstellung seines Impfstoffs gegen die Schweinegrippe erhält. Außerdem hatte Sinovac den Zuschlag über eine größere Lieferung des Grippeimpfstoffs Anflu für den Großraum Peking erhalten.
Zum anderen nimmt der Markt mit den aktuellen Kursexzessen bereits das Szenario vorweg, dass Sinovac das erste Unternehmen sein dürfte, das mit einem Impfstoff gegen die Schweinegrippe auf den Markt kommt. Es wird damit gerechnet, dass das chinesische Biotech-Unternehmen noch bis Ende der Woche von den Behörden mit einer entsprechenden Lizenz zur Herstellung des Impfstoffs ausgestattet wird.
sehr nützlich !!!!
bin bisher immer nur nach dem ariva intraday gegangen.
naja das is ja ein unterschied wie tag und nacht. :-)))
http://finance.yahoo.com/q?s=SVA&=
mc
jetzt merk ich mal , daß ich "immer" in der steinzeit getradet hab. ;-)))
wo bistn sonst so drin ?
gibts noch irgenwas lohnendes ?
bleibe bei meinem kursziel von 14$ bis ende der woche !
China set to approve 1-dose swine flu vaccines
China set to approve swine flu vaccines requiring only 1 dose
* On Wednesday September 2, 2009, 3:46 am EDT
o
Buzz up! 0
o Print
*
Companies:
o Sinovac Biotech Ltd.
BEIJING (AP) -- China will soon approve domestically developed swine flu vaccines that manufacturers say can protect people against the virus with only one dose, an encouraging development for health officials racing to prepare for an expected spike in cases this winter.
Related Quotes
Symbol Price Change §
SVA 10.46 0.00§
Chart for SINOVAC BIOTECH LTD
{"s" : "sva","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Many health authorities are assuming two doses of vaccine are necessary while they await the results of trials by drug makers around the world to determine the appropriate dosage.
China's State Food and Drug Administration said on its Web site it will make a decision this week on approving two vaccines that completed clinical trials last month and passed reviews by panels of about 40 experts. Four other vaccines are being reviewed, it said.
The vaccine makers, Sinovac Biotech Ltd. and Hualan Biological Engineering Inc., said the clinical trials show their products are effective in single doses when used on people aged three to 60 years. More than 3,000 people participated in the trials.
Sinovac says it has the capacity to produce up to 30 million doses of swine flu vaccine in a year while Hualan said it can make 160 million doses.
Stockpiling vaccines is China's latest move in its aggressive approach to contain the spread of swine flu in the country of 1.3 billion people and relatively limited medical resources. It has quarantined travelers on suspicion of contact with infected people and ordered schools to test students' temperatures.
The Health Ministry says around 3,700 cases of swine flu have been confirmed on the mainland -- none fatal.
China aims to have enough swine flu vaccine for 5 percent of the public by the end of the year, and although health officials have not released detailed vaccination plans, they have said health workers, public service workers and students are priority groups.
International health experts say swine flu has not been as severe as initially feared. At least 2,185 people have died, but most cases are mild and require no treatment. Worries remain that a rash of new infections could overwhelm hospitals and health authorities, particularly in poorer countries.
Buzz up! 0
Send
Share
die amis werdens heute mittag schon richten.
Since it was first detected last spring, the virus has continued to spread through the summer, taking the lives of more than 100 Californians, the governor said in a statement.
Schwarzenegger called on Californians to do their part by taking steps to slow the spread of the virus and prepare for the upcoming flu season.
"Each of us should be taking action now to prevent and prepare for the spread of H1N1," said Schwarzenegger. "Businesses need to be prepared that employees will not be in the office and parents need to plan for kids to be home from school. Everyone must do their part to limit the spread of the H1N1 virus."
According to Schwarzenegger, state public health and emergency response officials have been planning for the further escalation of the disease and the rollout of a vaccination program.
This includes expanding surveillance to detect increased pandemic activity, continuing development of clear guidelines for the public, working with local health departments to ensure healthcare facilities can respond to a surge in the need for patient care, and strengthening communication lines with medical providers and the public to get out information.
The California Department of Public Health (CDPH) will continue to work with federal and local partners on a vaccination program in California, the governor said.
"California has been preparing for the possibility of a flu pandemic for years so we stand ready to combat what could be a very severe flu season with the threat of H1N1," said Schwarzenegger. "The state of California is taking H1N1 very seriously, and I urge every Californian to take it seriously too."
He said people can all take important precautions to prevent getting sick or spreading the flu virus including covering their cough, washing their hands frequently and staying home when sick.
He said that the following actions should be taken to help protect against and prevent the spread of germs that cause the flu:
-- Cover the nose and mouth with a tissue when coughing or sneezing, throw the tissue in the trash after using it;
-- Wash hands often with soap, water or alcohol-based hand cleaners, especially after coughing or sneezing;
-- Avoid touching the eyes, nose or mouth to prevent germs from spreading;
-- Try to avoid close contact with sick people; and
-- Stay home when sick for seven days after symptoms begin or until becoming symptom-free for 24 hours so as to keep from infecting others and spreading the virus further.
Related Quotes
Symbol Price Change §
SVA 8.71 -1.75§
Chart for SINOVAC BIOTECH LTD
{"s" : "sva","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Experts said China's versions could boost global efforts to fight the virus if claims they work with just one dose are proven.
Many health authorities have assumed two doses would be needed to offer complete protection against the new H1N1 virus, so a single-dose vaccine means producers could distribute supplies to more people more quickly.
The World Health Organization said it was encouraged after reviewing details of trials of one of the two Chinese vaccines. However, experts said more test results were needed from other vaccine makers around the world to determine if one dose would be potent enough.
"Everybody is desperately hoping that one will do because then that's much easier to administer," said Jodie McVernon, a vaccine expert at the University of Melbourne who is involved in Australian trials of swine flu vaccines for young children. She said she had not seen the Chinese trial results.
China's State Food and Drug Administration said at least two vaccines are near approval after completing clinical trials last month and passing reviews by panels of about 40 experts this week. Another four vaccines are being reviewed, according to the agency.
The vaccine makers, Sinovac Biotech Ltd. and Hualan Biological Engineering Inc., said the clinical trials show they are effective in single doses when used on people aged 3 to 60 years.
International health experts say swine flu has not been as severe as initially feared. At least 2,185 people have died, but most other cases are mild and require no treatment. Worries remain that a rash of new infections could overwhelm hospitals and health authorities, particularly in poorer countries.
In about two weeks, the U.S. expects to announce initial trial results from its vaccine, which is the same type as China's Sinovac version, said Dr. Anthony Fauci of the National Institutes of Health, who is overseeing American swine-flu vaccine tests.
"From what I've seen and heard of the data, it looks encouraging," Fauci said of Sinovac's clinical trials. "This is very good news. Let's hope the material that we're using has similar results."
WHO said information provided by Sinovac shows that in trials, the vaccines were tested in three formulations of 15 microgram doses, and all gave antibody responses that satisfied regulatory criteria.
"We have no reason to doubt what Sinovac is reporting," said Melinda Henry, a WHO spokeswoman in Geneva. "Certainly if one dose proves sufficient to produce the desired immune response, this would be very encouraging in terms of augmenting the global supply of vaccine in the near future."
China aims to have enough swine flu vaccines for 5 percent of its population by the end of the year, Health Minister Chen Zhu said at a recent flu symposium in Beijing.
Chen said the government was still deciding who to vaccinate first, but health and public service workers and students are among groups likely to be given priority. Only 20 million people in China, or 1 percent of its population, get seasonal flu vaccinations every year, a small proportion compared to the U.S., where around a quarter of the population receive them.
Beyond meeting domestic needs, China's vaccine makers are eager to supply other countries, some of whom have expressed interest, if production can be ramped up.
"If we still have extra capacity, Sinovac is quite open to discuss the possible opportunities of H1N1 vaccine exports," the Beijing-based company said in an e-mailed response to questions.
Quality concerns would likely arise if China exports vaccines. Though China is a worldwide manufacturing center for pharmaceuticals, suppliers have been known to substitute cheaper and sometimes lethal ingredients. Tainted cough syrup was linked to several deaths in Central America and blood thinners made with contaminated product are suspected in dozens of deaths in the U.S. in recent years.
Last week, Mexico Health Secretary Jose Angel Cordova said Mexico is considering buying vaccines from China, at a cost that is more than 40 percent cheaper than other vaccines being offered to the government. But Mexico would want a guarantee that China's vaccine is safe and effective, he said.
China has said the two vaccines meet the international standards set by the European Medicines Agency, the EU agency responsible for the protection and promotion of public and animal health. However, data on the clinical trials has not yet been published.
Stockpiling vaccines is China's latest move in its aggressive approach to contain the spread of swine flu in the country of 1.3 billion people with relatively limited medical resources.
Chastised by foreign governments and its own people for initially covering up the 2002-03 outbreak of SARS, the communist government has taken strict measures against swine flu since the virus was first reported on the mainland in May.
These include blanket screening of travelers arriving from abroad at airports and quarantining anyone -- including entire foreign school groups and New Orleans Mayor Ray Nagin -- suspected of contact with an infected person.
Temperature checks are required to enter schools and many public buildings. Authorities have ordered schools to quarantine students at home if they come in close contact with swine flu patients. In eastern China, authorities said this week that school officials found responsible for a swine flu outbreak at a high school that led to 109 students being infected will be severely punished for not taking temperatures before classes started.
While criticized by some as excessive, Beijing has defended the measures, saying they've limited infections, with around 3,700 cases of swine flu reported on the mainland -- none fatal. In the U.S., more than 8,800 cases requiring hospitalization have been reported, with 556 deaths.
Buzz up! 0
Send
Share
The State Food and Drug Administration gave the green light on Thursday for the vaccine, which Sinovac says needs only one shot to be effective.
da haben sich manche wohl zu sehr auf eine weitere explosion eingestellt und schauen jetzt in die röhre.
trotz der guten nachrichten will der kurs einfach nicht mehr in die richtige richtung.
vielleicht hatten da so manchen analysten (besser börsenprofis) doch recht.
da war alles schon eingepreist.
keiner wußte genau wo die reise hingeht .
aber alle sind gefolgt.
bin gespannt ob sich da die nächste zeit noch was tut !
so da ich hier sowieso fast alleinunterhalter war , werd ich mich jetzt hier ausklinken.
allen börsianern
gute kurse
sosix